Filing identity and reporting period
Important discrepancy: The supplied filing is AspenBio Pharma, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2011—not a Riot Platforms, Inc. filing. The summary below reflects the filing text provided.
AspenBio was developing an acute appendicitis diagnostic test (AppyScore) and animal-health products, while also selling antigen products. Financial comparisons are for the three and six months ended June 30, 2011 versus the corresponding 2010 periods.
Financial results and liquidity
| Metric | Three months ended June 30, 2011 | Six months ended June 30, 2011 | Comparable 2010 period |
|---|---|---|---|
| Product sales | $55,322 | $152,638 | $59,132 and $201,265, respectively |
| Novartis license-fee revenue | $17,766 | $35,531 | $16,876 and $32,863, respectively |
| Gross profit / margin on product sales | $52,573 / 95% | $137,062 / 90% | $25,172 / 43% and $101,739 / 51%, respectively |
| Operating expenses | $2.817 million | $5.692 million | $3.429 million and $7.357 million, respectively |
| Operating loss | $2.746 million | $5.519 million | $3.387 million and $7.222 million, respectively |
| Net loss | $2.787 million | $5.593 million | $3.422 million and $7.294 million, respectively |
| Net loss per share | $0.35 | $0.70 | $0.44 and $0.95, respectively |
At June 30, 2011, cash and cash equivalents were $6.108 million and short-term investments were $0.952 million; management reported working capital of $4.667 million. Total assets were $12.026 million, total liabilities $5.697 million, and stockholders’ equity $6.329 million. Debt and other obligations totaled $2.598 million, primarily mortgage notes; approximately $1.607 million of the bank mortgage principal was estimated to be due in June 2013.
Six-month operating cash use was $4.347 million, investing cash provided was $1.770 million, and financing cash use was $0.223 million. Cash declined by $2.800 million from year-end 2010. The filing reports cash interest paid of $89,314 for the six-month period.
Changes versus the prior comparable periods
- Six-month product sales fell 24%, which management attributed mainly to suspending antigen production and shifting resources toward product development. Second-quarter sales declined 6%.
- Six-month gross margin on product sales improved to 90% from 51%, primarily because no fixed production costs were incurred in 2011.
- Six-month SG&A declined 26%, mainly reflecting lower stock-based compensation and option expense, no accrued employee incentives, and lower public-company costs. R&D declined 19% for the half year, although it increased 11% in the second quarter as AppyScore and secondary-marker work increased.
- Six-month net loss narrowed to $5.593 million from $7.294 million; operating cash use improved to $4.347 million from $6.446 million.
- Cash and cash equivalents plus short-term investments fell from $11.840 million at December 31, 2010 to $7.060 million at June 30, 2011.
Outlook, risks, contingencies, and unusual items
- Management expected continued near-term operating losses and said additional capital would likely be needed within twelve months. It believed available working capital would fund estimated needs for the remainder of 2011; a shelf registration statement had been filed and other financing alternatives were being explored.
- Management anticipated 2011 R&D spending would exceed 2010 levels, chiefly because of expected preclinical and clinical work. Forecast 2011 capital expenditures were $200,000–$300,000, expected to be funded from working capital.
- Novartis reported that the bovine-product pilot study did not meet its defined success criteria and requested a $900,000 refund. AspenBio reclassified that amount to accrued expenses; it was a current liability at June 30. The company was reviewing the final study report, and Novartis deferred its refund request pending that review.
- Three lawsuits related to AppyScore were disclosed: an individual securities-related action, a purported securities class action, and a shareholder derivative action. The company disputed the allegations; the derivative action was stayed. The filing does not quantify potential losses.
- After quarter-end, a one-for-five reverse stock split became effective July 29, 2011. Share and per-share amounts in the filing were retrospectively adjusted. Management reported disclosure controls were effective and no material change in internal control during the quarter.
Important facts for investors to verify
- Confirm the intended issuer and filing: the supplied document identifies AspenBio Pharma, not Riot Platforms.
- Assess the status and cash consequences of Novartis’s $900,000 refund request, the pilot-study review, and the future of the license agreement.
- Review financing needs and available liquidity against operating cash use, product-development spending, and management’s stated expectation that additional capital may be needed within twelve months.
- Check AppyScore’s development and regulatory progress, and the status and potential exposure of the disclosed litigation; the filing provides no clear loss estimate.
- Review the mortgage maturity schedule, especially the estimated $1.607 million bank principal due in June 2013, and confirm the post-quarter reverse-split-adjusted share count.